What Are Incretins?

Incretins are gut-derived peptide hormones that are released into the circulation in response to nutrient ingestion and that amplify glucose-stimulated insulin secretion from the pancreas. The term “incretin” originates from the phrase “intestinal secretin” — reflecting the early recognition that the gut plays an active endocrine role in regulating postprandial glucose metabolism beyond simply absorbing nutrients.

The incretin effect accounts for 50–70% of total postprandial insulin secretion in healthy individuals, making these hormones central regulators of metabolic homeostasis. Disruption of incretin signalling is observed across multiple metabolic disease states, making the incretin axis a critical area of investigation for metabolic peptide research.

GLP-1 and GIP: The Two Primary Incretins

Two peptide hormones define the incretin axis: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Despite sharing the functional definition of incretins, they differ markedly in their tissue sources, receptor distribution, and downstream effects beyond the pancreas.

Incretin Regulation of Glucose Homeostasis

The central mechanism by which incretins regulate blood glucose is the amplification of glucose-stimulated insulin secretion (GSIS) from pancreatic beta-cells. Both GLP-1 and GIP activate Gαs-coupled receptors on beta-cells, raising intracellular cAMP and activating PKA, which enhances insulin exocytosis in a glucose-dependent manner. Critically, this insulin-amplifying effect only occurs when blood glucose is elevated — when glucose is in the normal range, incretin signalling has minimal effect on insulin secretion, reducing the risk of hypoglycaemia in research models.

Additional Glucose-Regulatory Effects of GLP-1

• Suppression of glucagon from pancreatic alpha-cells (reduces hepatic glucose output)
• Delayed gastric emptying (reduces rate of glucose absorption from the gut)
• Stimulation of hepatic insulin signalling (improved hepatic glucose uptake)
• Promotion of beta-cell survival and potentially proliferation in preclinical models

Appetite Regulation via Incretin Pathways

Beyond their pancreatic roles, incretins — particularly GLP-1 — are potent modulators of appetite and energy intake through direct action on the central nervous system.

Central GLP-1 Signalling

GLP-1R is expressed on neurons in the hypothalamic arcuate nucleus (ARC), paraventricular nucleus (PVN), and the brainstem nucleus tractus solitarius (NTS). Activation of these receptors increases firing of anorexigenic POMC/CART neurons (appetite-suppressing) and reduces activity of orexigenic AgRP/NPY neurons (appetite-stimulating). GLP-1 also activates vagal afferent neurons in the gastrointestinal tract, sending satiety signals to the brainstem via the vagus nerve.

Emerging GIP CNS Signalling

While historically considered a peripheral hormone, GIPR expression has now been confirmed in the hypothalamus, area postrema, and other CNS regions. Research with dual GIP/GLP-1 agonists like Tirzepatide suggests that GIPR CNS activation contributes independently to appetite suppression, though the precise neuronal circuits remain under active investigation.

Incretin-Based Research Compounds

The incretin axis is one of the most pharmacologically tractable systems in metabolic biology. Research compounds targeting this system include:

• Selective GLP-1R agonists (e.g. semaglutide analogues): Tools for isolating pure GLP-1R biology
• Tirzepatide (GLP-1R + GIPR dual agonist): Tools for studying incretin synergy and GIPR contribution
• Retatrutide (GLP-1R + GIPR + GCGR triple agonist): Tools for multi-pathway metabolic crosstalk studies
• DPP-4 inhibitors: Tools that elevate endogenous GLP-1 and GIP by preventing their degradation

Frequently Asked Questions